Eli Lilly | LLY - Despesas De Vendas E Administração

Preço das Ações
984.89
Mudança Diária
-0.19 -0.02%
Mensal
-4.94%
Anual
19.42%
Q1 Previsão
955.33




Despesas De Vendas E Administração Alterar Data
AbbVie USD 3.89B 325M 2025-12
Abbott USD 3.13B 125M 2025-12
ALKERMES USD 187.2M 15.43M 2025-12
Amgen USD 1.94B 237M 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
Baxter International USD 761M 53M 2025-12
Biogen USD 545.2M 38.6M 2025-09
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Coherus Biosciences USD 26.02M 8.57M 2025-03
Drreddys Laboratories INR 26.92B 3.74B 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
Glaxosmithkline GBP 2.91B 817.89M 2025-09
J&J USD 6.75B 831M 2025-12
Medtronic 2.97B 159M 2025-09
Merck USD 2.85B 215M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Novartis USD 3.31B 134M 2025-09
Novartis USD 3.3B 137M 2025-09
Novo Nordisk DKK 17.44B 1.41B 2025-12
Perrigo USD 255.9M 10.2M 2025-12
Pfizer USD 4.08B 894M 2025-12
Phibro Animal Health USD 76.34M 10.54M 2024-12
Prestige Brands USD 29.67M 1.64M 2025-12
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.75B 455M 2025-12
Sanofi EUR 2.75B 455M 2025-12
United Therapeutics USD 190.6M 38.6M 2025-12
Zoetis USD 619M 40M 2025-12